Curasight AS (FRA:CUS) Days Sales Outstanding: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CUS Curasight AS FRA:CUS
19 GF Score
Price €1.26
! 2 Warning Signs
View Full Analysis

What is Curasight AS Days Sales Outstanding?

Curasight AS's average Accounts Receivable for the three months ended in Jun. 2026 was €0.00 Mil. Curasight AS's Revenue for the three months ended in Jun. 2026 was €0.00 Mil.

The historical rank and industry rank for Curasight AS's Days Sales Outstanding or its related term are showing as below:

FRA:CUS's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.98
* Ranked among companies with meaningful Days Sales Outstanding only.

Curasight AS's Days Sales Outstanding stayed the same from Jun. 2025 () to Jun. 2026 ().

Curasight AS  (FRA:CUS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Curasight AS Days Sales Outstanding Related Terms

Curasight AS Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for Curasight AS's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curasight AS Days Sales Outstanding Chart

Curasight AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Sales Outstanding
Get a 7-Day Free Trial - - - - -

Curasight AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:CUS vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison

For the Biotechnology subindustry, Curasight AS's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curasight AS Days Sales Outstanding vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curasight AS's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Curasight AS's Days Sales Outstanding falls into.


FRA:CUS
19GF Score
Curasight AS FRA:CUS
Days Sales Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curasight AS Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Curasight AS's Days Sales Outstanding for the fiscal year that ended in Dec. 2025 is calculated as

Days Sales Outstanding (A: Dec. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count ) / Revenue (A: Dec. 2025 )*Days in Period
=( ( + ) / 1 ) / 0*365
=0 / 0*365
=N/A

Curasight AS's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding (Q: Jun. 2026 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2026 ) + Accounts Receivable (A: Jun. 2026 )) / count ) / Revenue (A: Jun. 2026 )*Days in Period
=( ( + ) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curasight AS Business Description

Other Exchanges CURAS:Sweden
Address Ole Maaloes Vej 3, Kobenhavn N, Kobenhavn, DNK, DK-2200
Curasight AS is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors. The Company is focused on advancing its diagnostic and therapeutic platforms through key clinical milestones.
19GF Score

Get the complete analysis for FRA:CUS

Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.26
Price